Osteopontin is a therapeutic target that drives breast cancer recurrence
Yu Gu,Tarek Taifour,Tung Bui,Dongmei Zuo,Alain Pacis,Alexandre Poirier,Sherif Attalla,Anne-Marie Fortier,Virginie Sanguin-Gendreau,Tien-Chi Pan,Vasilios Papavasiliou,Nancy U Lin,Melissa E Hughes,Kalie Smith,Morag Park,Michel L Tremblay,Lewis A Chodosh,Rinath Jeselsohn,William J Muller
DOI: https://doi.org/10.1038/s41467-024-53023-9
2024-10-24
Abstract:Recurrent breast cancers often develop resistance to standard-of-care therapies. Identifying targetable factors contributing to cancer recurrence remains the rate-limiting step in improving long-term outcomes. In this study, we identify tumor cell-derived osteopontin as an autocrine and paracrine driver of tumor recurrence. Osteopontin promotes tumor cell proliferation, recruits macrophages, and synergizes with IL-4 to further polarize them into a pro-tumorigenic state. Macrophage depletion and osteopontin inhibition decrease recurrent tumor growth. Furthermore, targeting osteopontin in primary tumor-bearing female mice prevents metastasis, permits T cell infiltration and activation, and improves anti-PD-1 immunotherapy response. Clinically, osteopontin expression is higher in recurrent metastatic tumors versus female patient-matched primary breast tumors. Osteopontin positively correlates with macrophage infiltration, increases with higher tumor grade, and its elevated pathway activity is associated with poor prognosis and long-term recurrence. Our findings suggest clinical implications and an alternative therapeutic strategy based on osteopontin's multiaxial role in breast cancer progression and recurrence.